HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3740-3750

  Knowles, Lynn M ^a   Stabile, Laura P ^a   Egloff, Ann Marie ^a   Rothstein, Mary E ^a   Thomas, Sufi M ^a   Gubish, Christopher T ^a   Lerner, Edwina C ^a   Seethala, Raja R ^a   Suzuki, Shinsuke ^a   Quesnelle, Kelly M ^a   Morgan, Sarah ^a   Ferris, Robert L ^a   Grandis, Jennifer R ^a   Siegfried, Jill M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NEUTRALIZING ANTIBODY; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FIBROBLAST; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; WOUND HEALING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PARACRINE COMMUNICATION; PIPERAZINES; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; SIGNAL TRANSDUCTION; STRESS, MECHANICAL; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 66649131963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3252     Document Type: Article

References (50)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925 (Pubitemid 37493640)
2. Maulik G, Madhiwala P, Brooks S, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002;6:539-553 (Pubitemid 44149770)
3. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol 2006;1:7-9. (Pubitemid 47164015)
4. Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer 2007;6:69.
5. Lee KH, Choi EY, Hyun MS, et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 2007;39:208-215 (Pubitemid 47000367)
6. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26. (Pubitemid 40732764)
7. Lothaire P, De Azambuja E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation. Head Neck 2006;28:256-269 (Pubitemid 43269893)
8. De Herdt MJ, Baatenburg De Jong RJ. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci 2008;13:2516-2526
9. Lo Muzio L, Farina A, Rubini C, et al. Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumor Biol 2006;27:115-121
10. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and Src pathways in head and neck cancer. Semin Oncol 2008;35:286-297
11. Heo DS, Snyderman C, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167-5175 (Pubitemid 19239363)
12. Sacks PG, Parnes SM, Gallick GE, et al. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 1988;48:2858-2866 (Pubitemid 18137762)
13. Grenman R, Carey TE, McClatchey KD, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 1991;67:2741-2747
14. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007;43:415-432 (Pubitemid 46123982)
15. Stabile LP, Rothstein ME, Keohavong P, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008;7:1913-1922
16. Stabile LP, Lyker JS, Huang L, Siegfried JM. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 2004;11:325-335 (Pubitemid 38220085)
17. Tatsumi R, Anderson JE, Nevoret CJ, Halevy O, Allen RE. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol 1998;194:114-128 (Pubitemid 28115263)
18. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001;61:5911-5918 (Pubitemid 32769111)
19. Daly AJ, McIlreavey L, Irwin CR. Regulation of HGF and SDF-1 expression by oral fibroblasts - implications for invasion of oral cancer. Oral Oncol 2008;44:646-651
20. Koon EC, Ma PC, Salgia R, et al. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2008;18:976-984
21. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 2007;97:368-377 (Pubitemid 47196754)
22. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488 (Pubitemid 40270177)
23. Puri N, Ahmed S, Janamanchi V, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007;13:2246-2253 (Pubitemid 46649894)
24. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006;66:352-361 (Pubitemid 43166042)
25. Wang X, Le P, Liang C, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2003;2:1085-1092
26. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-4417 (Pubitemid 46815090)
27. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-Dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-7355 (Pubitemid 37413476)
28. Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL. Small molecule c-met inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck 2008;30:991-1000.
29. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (met) in human breast carcinoma. Am J Cardiovasc Pathol 1996;148:225-232 (Pubitemid 26022451)
30. Ma PC, Jagadeesh S, Jagadeeswaran R. c-MET expression/activation, functions, and mutations in non-small cell lung cancer [abstract]. Philadelphia (PA): AACR; 2004, p. 430, Abstract nr 1875.
31. Kim CH, Moon SK, Bae JH, et al. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006;126:88-94. (Pubitemid 41769745)
32. Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998;108:1413-1417 (Pubitemid 28411378)
33. Kaji M, Yonemura Y, Liu X, Terada I, Yamamoto H. Participation of c-met in the progression of human gastric cancer: anti-c-met oligonucleotides inhibit proliferation of invasiveness of gastric cancer cells. Cancer Gene Ther 1996;6:393-404. (Pubitemid 126732461)
34. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995;55:1129-1138
35. Galeazzi E, Olivero M, Gervasio FC, et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol Suppl 1997;254:S138-43. (Pubitemid 27110381)
36. Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002;62:589-596 (Pubitemid 34106436)
37. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001;96:41-54. (Pubitemid 32147684)
38. Tuynman JB, Lagarde SM, Ten Kate FJW, Richel DJ, Van Lanschot JJB. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008;98:1102-1108
39. Siegfried JM, Luketich JD, Stabile LP, Christie N, Land SR. Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung. Chest 2004;125:116-119 (Pubitemid 38648345)
40. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-1633 (Pubitemid 24116158)
41. Kim CH, Lee JS, Kang SO, Hong SP, Kahng H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol 2007;43:1021-1025 (Pubitemid 47532778)
42. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-1555 (Pubitemid 30175676)
43. Akervall J, Guo X, Qian CN, et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004;10:8204-8213 (Pubitemid 40053379)
44. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-3956
45. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007;67:9304-9314 (Pubitemid 47535919)
46. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043 (Pubitemid 46799492)
47. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011.
48. Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 1999;109:687-693 (Pubitemid 29227910)
49. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: Biological and therapeutic implications. Lab Invest 2008;88:342-353
50. Zarnegar R, DeFrances MC, Oliver L, Michalopoulos G. Identification and partial characterization of receptor binding sites for HGF on rat hepatocytes. Biochem Biophys Res Commun 1990;173:1179.